Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Lahera

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Scientific Reports|April 12, 2017
Human PrimPol activity is enhanced by RPAMaría I Martínez-Jiménez, Antonio Lahera, Luis Blanco
Molecular Carcinogenesis|September 15, 2023
The JAK3<sup>Q988P</sup> mutation reveals oncogenic potential and resistance to ruxolitinibAntonio Lahera, Laura Vela-Martín, Pablo Fernández-Navarro, et al.
NPJ Precision Oncology|July 20, 2024
PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBLAntonio Lahera, Laura Vela-Martín, Pablo Fernández-Navarro, et al.
Molecular Oncology|April 9, 2026
Differential expression of cancer-related genes supports prediction of poor response to first-line treatments in T-ALL pediatric patients with high minimal residual diseaseAntonio Lahera, Laura Vela-Martín, Pablo Fernández-Navarro, et al.
British Journal of Haematology|February 14, 2023
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasmsAntonio Lahera, Pilar López-Nieva, Hernán Alarcón, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Scientific Reports|April 12, 2017
Human PrimPol activity is enhanced by RPAMaría I Martínez-Jiménez, Antonio Lahera, Luis Blanco
Molecular Carcinogenesis|September 15, 2023
The JAK3<sup>Q988P</sup> mutation reveals oncogenic potential and resistance to ruxolitinibAntonio Lahera, Laura Vela-Martín, Pablo Fernández-Navarro, et al.
NPJ Precision Oncology|July 20, 2024
PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBLAntonio Lahera, Laura Vela-Martín, Pablo Fernández-Navarro, et al.
Molecular Oncology|April 9, 2026
Differential expression of cancer-related genes supports prediction of poor response to first-line treatments in T-ALL pediatric patients with high minimal residual diseaseAntonio Lahera, Laura Vela-Martín, Pablo Fernández-Navarro, et al.
British Journal of Haematology|February 14, 2023
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasmsAntonio Lahera, Pilar López-Nieva, Hernán Alarcón, et al.
Pageof 1